Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 890 of 6351
-
New antibody drug shows promise for severe asthma sufferers
Disease control CompletedThis is a phase II, multicenter, double-blind, randomized, parallel group, placebo-controlled clinical study to evaluate the effect of three doses of TQC2731 on Annualized Asthma Exacerbation Rates(AAER) in adult subjects with poor control of severe asthma. It is estimated that 2…
Phase 2 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
New combo therapy aims to shrink rare melanomas before surgery
Disease control Recruiting nowThe goal of this clinical research study is to learn if pre-operative radiation therapy after starting immune checkpoint inhibition can help patients with sinonasal or anorectal melanoma have better outcomes
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New drug combo shows promise for tough ovarian cancer
Disease control OngoingThis research study is being done to test the efficacy and safety of combining the study drugs pembrolizumab and lenvatinib in patients with clear cell ovarian cancer. The names of the study drugs involved in this study are: * Lenvatinib * Pembrolizumab
Phase 2 • Sponsor: Elizabeth K. Lee MD • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
New hope for lymphoma patients: drug may boost CAR T-Cell success
Disease control Recruiting nowTo learn if loncastuximab tesirine (called "lonca" in this informed consent form) can help to control large B-cell lymphoma that is relapsed or refractory after receiving CAR T-cell therapy. The safety and possible effects of the study therapy will also be studied.
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
New drug combo targets hidden HER2 in breast cancer brain tumors
Disease control Recruiting nowThe purpose of this research is to look at the safety and effectiveness of a HER2-targeted therapy neratinib when given with capecitabine, a chemotherapy, for breast cancer patients with brain metastases whose tumors were HER2-negative by standard tests but showed abnormal HER2 a…
Phase 2 • Sponsor: University of Rochester • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
New drug cocktail aims to control aggressive blood cancers
Disease control Recruiting nowTo learn if the combination of cladribine, cytarabine, venetoclax, and azacitidine can help to control higher-risk myelodysplastic syndrome (MDS) with excess blasts and/or higher-risk chronic myelomonocytic leukemia (CMML).
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New combo therapy aims to wipe out stubborn myeloma cells
Disease control OngoingThis phase II trial test whether combination chemotherapy works to improve blood test results in patients with high-risk multiple myeloma. Chemotherapy drugs, such as carfilzomib, daratumumab, lenalidomide, and dexamethasone, work in different ways to stop the growth of cancer ce…
Phase 2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Massive flu vaccine trial: does a stronger shot protect seniors better?
Prevention CompletedThe purpose of this pragmatic randomized trial is to evaluate the relative vaccine effectiveness of high-dose quadrivalent influenza vaccine (QIV-HD) vs. standard-dose quadrivalent influenza vaccine (QIV-SD) in older adults. Participants will be randomized 1:1 to either QIV-HD or…
Phase 4 • Sponsor: Tor Biering-Sørensen • Aim: Prevention
Last updated Jun 26, 2026 15:46 UTC
-
New combo therapy targets rare, aggressive kidney cancer
Disease control OngoingTo learn if the combination of nivolumab and relatlimab can help to control renal medullary carcinoma (RMC) that is locally advanced or metastatic (has spread).
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Could a common heart pill save Preemies' eyesight?
Prevention Recruiting nowExtremely premature infants are at risk of developing a potentially blinding eye disease, called retinopathy of prematurity (ROP). Currently available treatment, consisting of laser surgery or injection of drugs into the eye balls, may prevent most but not all cases of permanent …
Phase 2 • Sponsor: University of Zurich • Aim: Prevention
Last updated Jun 27, 2026 12:30 UTC
-
Lung cancer drug order trial aims to extend life and ease side effects
Disease control Recruiting nowThe purpose of this study is to evaluate the optimal sequence of EGFR-inhibitors in lung cancer patients with EGFR-positive tumors not amenable for curative treatment. Life quality, adverse effects and tumor response will be evaluated and analyses of obtained blood and tumor samp…
Phase 3 • Sponsor: Region Skane • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
Can a newer prostate drug outperform the standard?
Disease control CompletedObjective: To evaluate the efficacy and safety of Silodosin Capsules in the treatment of Benign Prostatic Hyperplasia (BPH) with Lower Urinary Tract Symptoms (LUTS) compared with Tamsulosin Hydrochloride Sustained Release Capsules. Study design: A multicenter, prospective, rando…
Phase 4 • Sponsor: Xintian Pharmaceutical • Aim: Disease control
Last updated Sep 09, 2026 23:00 UTC
-
New vaccine combo aims to tame chronic hepatitis b
Disease control CompletedThis is an open-label study to determine the efficacy, safety, tolerability and immunogenicity of ChAdOx1-HBV and MVA-HBV, together VTP-300, in combination with low-dose nivolumab, in patients with chronic HBV who are virally suppressed with oral anti-viral therapies.
Phase 2 • Sponsor: Barinthus Biotherapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
Can an experimental infusion reach the brain to fight Alzheimer's?
Disease control CompletedThe purpose of this study is to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of MK-2214 in adults with mild cognitive impairment or mild-to-moderate Alzheimer's Disease. The primary hypothesis (Part 1) is that at a generally well-tolerated dose level, t…
Phase 1 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Hope for Tough-to-Treat bone cancer: new combo trial launches
Disease control OngoingThe purpose of this study is to measure the benefit of adding abemaciclib to chemotherapy (irinotecan and temozolomide) for Ewing's sarcoma that has come back or did not respond to treatment. This trial is part of the CAMPFIRE master protocol, which is a platform to speed develop…
Phase 2 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Triple-Drug cocktail targets kidney cancer brain metastases
Disease control Recruiting nowA Phase II Study of Nivolumab with Ipilimumab and Cabozantinib in Patients with Untreated Renal Cell Carcinoma Brain Metastases
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New PET scan agent spots prostate cancer missed by standard tests
Diagnosis CompletedThe aim of this study is to determine the safety and efficacy of 64Cu-SAR-BBN and determine the ability of 64Cu-SAR-BBN Positron emission tomography (PET)/computed tomography (CT) to correctly detect the recurrence of prostate cancer in participants with prostate-specific membran…
Phase 2 • Sponsor: Clarity Pharmaceuticals Ltd • Aim: Diagnosis
Last updated Jun 27, 2026 07:57 UTC
-
Double biologic punch: new combo trial for ulcerative colitis
Disease control OngoingThe purpose of this study is to evaluate the efficacy and safety of JNJ-78934804 as compared to guselkumab and golimumab in participants with moderately to severely active ulcerative colitis who have had an inadequate initial response, loss of response, or intolerance to one or m…
Phase 2 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New combo shows promise against tough skin cancer
Disease control OngoingThe purpose of this single arm, multi-national clinical trial in patients with metastatic or unresectable melanoma is to evaluate the BOR and compare it to historical data on patients on anti-PD1 treatment with pembrolizumab alone.
Phase 2 • Sponsor: Evaxion Biotech A/S • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
New pill targets Hard-to-Treat cancers in early trial
Disease control OngoingThe purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of escalating doses of RMC-6291 (KRAS G12C(ON) inhibitor) monotherapy in adult subjects with advanced solid tumors and to identify the maximum tolerated dose (MTD), and the recommended Ph…
Phase 1 • Sponsor: Revolution Medicines, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC